Mylan (NASDAQ:MYL) had its price objective cut by Citigroup from $50.00 to $48.00 in a report published on Thursday. They currently have a buy rating on the stock.

Several other research analysts have also weighed in on MYL. Leerink Swann dropped their price objective on shares of Mylan from $53.00 to $47.00 and set an outperform rating on the stock in a research note on Thursday. BidaskClub lowered shares of Mylan from a buy rating to a hold rating in a research note on Friday, June 22nd. Raymond James lowered shares of Mylan from a strong-buy rating to an outperform rating in a research note on Thursday. ValuEngine upgraded shares of Mylan from a sell rating to a hold rating in a research note on Wednesday, June 13th. Finally, Cantor Fitzgerald set a $41.00 price target on shares of Mylan and gave the stock a hold rating in a research note on Friday, June 29th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company’s stock. Mylan currently has an average rating of Buy and a consensus price target of $46.07.

Mylan stock traded up $0.60 during trading hours on Thursday, hitting $37.21. The company had a trading volume of 5,601,928 shares, compared to its average volume of 5,095,309. The firm has a market cap of $18.87 billion, a PE ratio of 8.16, a P/E/G ratio of 1.17 and a beta of 1.34. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.65 and a current ratio of 1.29. Mylan has a fifty-two week low of $29.39 and a fifty-two week high of $47.82.

Mylan (NASDAQ:MYL) last released its quarterly earnings data on Wednesday, August 8th. The company reported $1.07 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.22 by ($0.15). The company had revenue of $2.81 billion during the quarter, compared to analyst estimates of $2.95 billion. Mylan had a net margin of 3.90% and a return on equity of 18.48%. The firm’s quarterly revenue was down 5.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.10 EPS. equities analysts anticipate that Mylan will post 4.76 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Menora Mivtachim Holdings LTD. boosted its holdings in shares of Mylan by 219.1% during the 1st quarter. Menora Mivtachim Holdings LTD. now owns 7,057,501 shares of the company’s stock worth $290,557,000 after buying an additional 4,845,703 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Mylan by 32.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 9,408,218 shares of the company’s stock worth $340,012,000 after buying an additional 2,284,545 shares during the period. OppenheimerFunds Inc. boosted its holdings in shares of Mylan by 221.4% during the 1st quarter. OppenheimerFunds Inc. now owns 1,607,915 shares of the company’s stock worth $66,198,000 after buying an additional 1,107,667 shares during the period. Kornitzer Capital Management Inc. KS bought a new stake in shares of Mylan during the 2nd quarter worth $38,614,000. Finally, Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of Mylan by 522.2% during the 2nd quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,131,937 shares of the company’s stock worth $40,908,000 after buying an additional 950,000 shares during the period. Institutional investors own 83.39% of the company’s stock.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Further Reading: NASDAQ

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.